Suppr超能文献

外周动脉疾病患者使用他汀类药物的情况。

Statin use in patients with peripheral arterial disease.

作者信息

Harris Sheena K, Roos Matt G, Landry Gregory J

机构信息

Oregon Health and Science University, Portland, Ore.

Oregon Health and Science University, Portland, Ore.

出版信息

J Vasc Surg. 2016 Dec;64(6):1881-1888. doi: 10.1016/j.jvs.2016.08.094.

Abstract

BACKGROUND

Statins are recommended for use in patients with peripheral arterial disease (PAD) to reduce cardiovascular events and mortality. However, much of the data regarding benefits of statins stem from the cardiovascular literature. Here, we review the literature regarding statin use specifically in patients with PAD regarding its effects on cardiovascular events and mortality, limb-related outcomes, statin use after endovascular interventions, statin dosing, and concerns about statins.

METHODS

We performed a literature review using PubMed for literature after the year 2000. Search terms included "statins," "peripheral arterial disease," "peripheral vascular disease," "lipid-lowering medication," and "cardiovascular disease."

RESULTS

There is good evidence of statins lowering cardiovascular events and cardiovascular-related mortality in patients with PAD. Though revascularization rates were reduced with statins, amputation rates and amputation-free survival did not improve. Small randomized controlled trials show that patients taking statins can slightly improve pain-free walking distance or pain-free walking time, although the extent of the effect on quality of life is unclear. Statin use for patients undergoing endovascular interventions is recommended because of the reduction of postoperative cardiovascular events. Not enough data exist to support local effects of systemic statin therapy, such as prevention of restenosis. For statin dosing, there is little increased benefit to intense therapy compared with the adverse effects, whereas moderate-dose therapy has significant benefits with very few adverse effects. Adverse effects of moderate-dose statin therapy are rare and mild and are greatly outweighed by the cardiovascular benefits.

CONCLUSIONS

There is strong evidence to support use of statins in patients with PAD to reduce cardiovascular events and mortality. Use in patients undergoing open and endovascular interventions is also recommended. Statin use may reduce the need for revascularization, but reductions in amputation have not been shown. Moderate-dose statin therapy is safe, and the minor risks are greatly outweighed by benefits.

摘要

背景

他汀类药物被推荐用于外周动脉疾病(PAD)患者,以降低心血管事件和死亡率。然而,关于他汀类药物益处的许多数据来自心血管领域的文献。在此,我们回顾关于他汀类药物在PAD患者中的应用的文献,内容涉及他汀类药物对心血管事件和死亡率、肢体相关结局、血管内介入治疗后他汀类药物的使用、他汀类药物剂量以及对他汀类药物的担忧。

方法

我们使用PubMed对2000年以后的文献进行了文献综述。检索词包括“他汀类药物”“外周动脉疾病”“外周血管疾病”“降脂药物”和“心血管疾病”。

结果

有充分证据表明他汀类药物可降低PAD患者的心血管事件和心血管相关死亡率。尽管他汀类药物使血运重建率降低,但截肢率和无截肢生存率并未改善。小型随机对照试验表明,服用他汀类药物的患者可略微改善无痛行走距离或无痛行走时间,尽管对生活质量的影响程度尚不清楚。由于可降低术后心血管事件,建议对接受血管内介入治疗的患者使用他汀类药物。尚无足够数据支持全身他汀类药物治疗的局部效应,如预防再狭窄。对于他汀类药物剂量,强化治疗与不良反应相比益处增加不多,而中等剂量治疗具有显著益处且不良反应极少。中等剂量他汀类药物治疗的不良反应罕见且轻微,心血管益处远远超过不良反应。

结论

有强有力的证据支持在PAD患者中使用他汀类药物以降低心血管事件和死亡率。也建议在接受开放手术和血管内介入治疗的患者中使用。他汀类药物的使用可能会减少血运重建的需求,但尚未显示出截肢率降低。中等剂量他汀类药物治疗是安全的,轻微风险与益处相比微不足道。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验